Bio-Reference | GenomeWeb


The revenue surge was largely due to revenues from Bio-Reference Laboratories, which Opko acquired in August 2015.

Following the close of the deal, Opko's diagnostic services will be merged with Bio-Reference's operations.

Bio-Reference Laboratories, Cepheid, Exact Sciences, and NanoString all saw their shares rise in June. Sequenom topped the list of decliners.

The deal is still subject to other closing conditions including the approval of BRL's shareholders.

The firm said that revenues per patient were up 3 percent, while the number of patients served grew 8 percent. 

Opko plans to leverage BRL's national marketing, sales, and distribution resources to enhance the sale of its blood-based 4Kscore test for aggressive prostate cancer.

The company has amended and restated a credit facility and a secured revolving note to increase the available borrowing amount for each to up to $120 million.

The company's CEO noted the recent launches of new NGS cancer panels and said that more genomics offerings are planned for the year.

NEW YORK (GenomeWeb) – While industry observers might disagree about whether GeneDx's decision to apply for inter partes review (IPR) of 11 patents held by Myriad Genetics will work in its favor, they generally concur that it is a quicker and less costly strategy than litigation.

NEW YORK (GenomeWeb) – BioReference Laboratories today reported that its third quarter revenues climbed 20 percent year over year and were the highest recorded quarterly revenues in the firm's history.


In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.